Welcome to our dedicated page for Applied Genetic news (Ticker: AGTC), a resource for investors and traders seeking the latest updates and insights on Applied Genetic stock.
The AGTC (Applied Genetic Technologies Corporation) news archive on Stock Titan covers the company’s history as a clinical-stage biotechnology developer of adeno-associated virus (AAV)-based gene therapies for rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. News releases repeatedly describe AGTC’s focus on inherited retinal diseases, with its most advanced clinical programs in X-linked retinitis pigmentosa (XLRP) and achromatopsia due to CNGB3 variants (ACHM CNGB3).
Readers will find detailed coverage of the strategic transaction in which a portfolio company of Syncona Limited agreed to acquire AGTC through a tender offer and subsequent merger. Multiple releases from October through December 2022 outline the tender offer terms, the board’s unanimous recommendation, reminders to shareholders about tender deadlines, and the final confirmation that the acquisition closed and AGTC became an indirect, wholly owned subsidiary of Syncona Limited, with its common stock delisted from the Nasdaq Global Stock Market.
The archive also includes earlier corporate updates, such as announcements about AGTC’s participation in investor conferences and reiterations of its development strategy in AAV-based gene therapy, inherited retinal disease programs, and preclinical work in optogenetics, otology and CNS disorders. In addition, later news from Beacon Therapeutics references laru-zova (laruparetigene zovaparvovec), described in a presentation title as “AGTC-501,” providing continuity for those tracking the historical XLRP program originally developed at AGTC.
Investors, researchers and industry observers can use this news page to review AGTC’s public communications, understand the rationale and structure of the Syncona acquisition, and follow how AGTC’s legacy XLRP asset is referenced in subsequent clinical trial updates from Beacon Therapeutics.
Applied Genetic Technologies Corporation (AGTC) announced Jonathan I. Lieber as the new CFO, effective immediately. With 30 years of experience in financial leadership and investment banking, Lieber is expected to enhance AGTC's strategic planning and operational efficiency. AGTC focuses on developing gene therapies for rare retinal diseases, with ongoing clinical trials for X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM). The company aims to address unmet medical needs in ophthalmology and has established partnerships to support its innovation efforts.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced participation in the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021. The company is focused on developing gene therapies for rare diseases and is currently conducting human clinical trials using AAV-based technologies.
AGTC's advanced programs aim to treat conditions like X-linked retinitis pigmentosa and achromatopsia. Interested parties can access audio webcasts of the presentation via the company's website.
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a leader in gene therapies for rare diseases, will participate in the 2021 Wells Fargo Virtual Healthcare Conference on September 10, 2021, at 8:40 AM E.T. Management will engage in a fireside chat, presenting insights on their ongoing clinical trials and advanced gene therapy programs. AGTC's research focuses on inherited retinal diseases, specifically X-linked retinitis pigmentosa and achromatopsia. Interested parties can access audio webcasts at AGTC's investor relations site.
Summary not available.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) is sponsoring the Achroma Corp No Roadblocks program, which provides tinted glasses and contact lenses to individuals with achromatopsia (ACHM). This program aims to assist affected individuals in obtaining essential vision aids for bioptic driving, enhancing their independence. ACHM, caused by genetic mutations, results in severe visual impairment and light sensitivity. AGTC is actively developing AAV-based gene therapies for ACHM and other inherited retinal diseases, emphasizing its commitment to improving the quality of life for patients.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) has appointed Dr. Yehia Hashad to its Board of Directors, enhancing its leadership team with his extensive experience in pharmaceuticals, particularly in ophthalmology. With over 25 years in the industry, Dr. Hashad has spearheaded drug development strategies, especially in areas of high unmet medical need. His expertise is expected to guide AGTC in advancing its gene therapies targeting rare retinal diseases, positioning the company for significant advancements in its clinical trials.
AGTC announced its Executive Director of Global Patient Advocacy, Jill Dolgin, will participate in a panel at the Envision Virtual Conference East on August 20-21, 2021. The discussion will focus on genetic testing and gene therapy for rare inherited retinal diseases (IRDs). Dr. Dolgin will be joined by other experts to address patient concerns about these therapies. AGTC is involved in clinical trials using AAV-based gene therapies to potentially improve vision for patients with conditions like X-linked retinitis pigmentosa and achromatopsia.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced its participation in several virtual investor conferences. Sue Washer, President & CEO, will engage in a fireside chat at the BTIG Virtual Biotechnology Conference on August 9, 2021, and join a panel on ophthalmic gene therapy at the Wedbush PacGrow Healthcare Conference on August 11, 2021. Additionally, her presentation at the H.C. Wainwright Ophthalmology Conference will be available for on-demand viewing starting August 17, 2021. For further details, audio replays will be accessible on the Company's website.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) will host a virtual R&D Day on July 22, 2021, from 10:00 am to 1:00 pm ET. The event will highlight 12-month data from ongoing Phase 1/2 clinical trials for X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM). Key discussions will cover light sensitivity, genetics, and the company’s new 21,000 sq. ft. cGMP manufacturing facility in Florida. AGTC aims to advance therapies for rare retinal diseases and will provide a comprehensive analysis of its clinical and regulatory processes during this webcast.
Applied Genetic Technologies Corporation (AGTC) announced ongoing clinical activities for its ACHM B3 candidate, with dosing expected to complete in August 2021. The company reported positive 12-month data from achromatopsia Phase 1/2 trials, highlighting improvements in visual sensitivity and safety. AGTC plans to advance ACHM B3 to the next clinical stage and is drafting an End-of-Phase 2 briefing for the FDA. However, the ACHM A3 trial didn't show consistent biologic activity, raising concerns. Upcoming data from younger patients may provide further insights.